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Abstract
Mapping and diagnosis of infections by the three major schistosome species (Schistosoma haematobium, S. mansoni
and S. japonicum) has been done with assays that are known to be specific but increasingly insensitive as prevalence
declines or in areas with already low prevalence of infection. This becomes a true challenge to achieving the goal of
elimination of schistosomiasis because the multiplicative portion of the life-cycle of schistosomes, in the snail vector,
favors continued transmission as long as even a few people maintain low numbers of worms that pass eggs in their
excreta. New mapping tools based on detection of worm antigens (circulating cathodic antigen – CCA; circulating
anodic antigen – CAA) in urine of those infected are highly sensitive and the CAA assay is reported to be highly specific.
Using these tools in areas of low prevalence of all three of these species of schistosomes has demonstrated that more
people harbor adult worms than are regularly excreting eggs at a level detectable by the usual stool assay (Kato-Katz) or
by urine filtration. In very low prevalence areas this is sometimes 6- to10-fold more. Faced with what appears to be a
sizable population of “egg-negative/worm-positive schistosomiasis” especially in areas of very low prevalence, national
NTD programs are confounded about what guidelines and strategies they should enact if they are to proceed toward a
goal of elimination. There is a critical need for continued evaluation of the assays involved and to understand
the contribution of this “egg-negative/worm-positive schistosomiasis” condition to both individual morbidity
and community transmission. There is also a critical need for new guidelines based on the use of these more sensitive
assays for those national NTD programs that wish to move forward to strategies designed for elimination.
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Background
Historically, schistosomiasis has been diagnosed and
mapped by multiple different methods that have relied on
microscopy of excreta [1–5] for schistosome eggs,
detection of antibodies against schistosome antigens [6–8],
viable parasitological assays such as egg hatching from ex-
creta [9] or frank signs of morbidity [10]. Most commonly,
infection by Schistosoma haematobium has been mapped
using questionnaires, gross hematuria, micro-hematuria
(by hemastix) or urine filtration followed by microscopy
for S. haematobium eggs [3–5, 10]. S. mansoni and S.
japonicum, however, are most commonly mapped by
Kato-Katz (KK) stool microscopy [1] or some other stool
concentration technique [5, 11] to observe schistosome
eggs. These assays have been entirely satisfactory for pro-
grams focused on bringing high levels of prevalence and
intensity of infection down to “manageable” points where
severe morbidity is taken to a minimum and subtle mor-
bidities lessened [12, 13]. However, based on World Health
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Assembly Resolution 54.19 in 2001, purchases and dona-
tions of praziquantel (PZQ) and enabling organizations
such as the Schistosomiasis Control Initiative and others,
many countries have implemented Mass Drug Administra-
tion (MDA) programs leading to lower countrywide preva-
lence and intensity levels of schistosomiasis. Some
countries, such as Japan, China and Egypt have led the way
with 50-60 yearlong programs to achieve this end. All of
this has led to the World Health Assembly (WHA)
Resolutions 65.21 and 66.12, in 2012 and 2013, respect-
ively, and the London Declaration on Neglected Tropical
Diseases (NTDs) in 2012 [14]. The WHA resolutions and
the subsequent WHO/NTD Road Map in 2011 [15] now
seek to evolve, where feasible, the programmatic focus
from morbidity control to elimination of schistosomiasis
as a public health problem and eventually to elimination
of transmission. The London Declaration assists this shift
in goals through donations by companies and government
and non-government agencies. In regard to schistosomia-
sis, this is clearly manifested by the major donation by
Merck-KGaA of praziquantel (PZQ) for morbidity control
and elimination. A real shift in emphasis to these goals of
elimination will require substantial changes based on
comprehensively knowing and following the on-the-
ground situation in regard to the prevalence and intensity
of human schistosome infections, coupled with conscious
and meaningful changes in public health program strat-
egies and tools. Although there is no “gold standard” for
detecting schistosome infections, that knowledge and
those strategies and tools will need to be driven by map-
ping and diagnostic assays that are more sensitive than
what have served the programs well in the past. Those
goals will also need to be founded on new guidelines and
the implementation of new policies predicated on the use
of the more sensitive assays. This commentary will focus
primarily on the currently relevant case of mapping of S.
mansoni infection by the use of the commercially available
urine Point-of-care Circulating Cathodic Antigen (POC-
CCA) assay in comparison with the stool KK assay and
discuss the challenges and conundrums raised in changing
to more sensitive assays, and the guidelines and strategies
needed for moving towards elimination of schistosomiasis.
An available urine assay for mapping S. mansoni
infections – challenges and opportunities
Based on detection of the Circulating Cathodic Antigen
(CCA), first reported on in the mid-1970s [16–18], the
commercially available POC-CCA cassette assay to detect
CCA from S. mansoni worms in urine became available in
2008. Its major advantages are the use of urine rather than
stool samples, the ability to do the assay either on-the-
spot or on stored urines, and that the assay does not
require a microscope and highly trained microscopists.
These characteristics have provided an impetus to utilize
this assay for the mapping of S. mansoni in many studies
[19] and now some national programs. The drawbacks of
using this assay compared to the KK stool assay are that
1) it does not detect Soil-transmitted Helminth (STH)
eggs, 2) does not provide a quantified number of eggs per
gram of stool, and 3) presents a challenge regarding the
uniform interpretation of “trace” readings.
The limitation in quantification of eggs is somewhat
mitigated because the density of the band observed in a
positive test bears some relationship to assessment of
eggs per gram by KK [19]. Also, electronic POC-CCA
readers can assist in quantifying the bands [20] (personal
observation, Carl H. Campbell, Jr.).
Of more concern is the assessment of what constitutes
a “Trace” reading. The manufacturer maintains that a
“trace” (i.e., a faint band) should be considered a posi-
tive, but data from multiple sites and comparisons con-
ducted in Kenya suggest that different people do or do
not see light bands in the assay. In addition, when some
investigators see a faint band they have chosen to refer
to this as “trace-negative” and dealt with it as a negative
assay in their analyses. However, in areas of low preva-
lence and intensity even if trace readings are considered
negative the prevalence by POC-CCA is uniformly
higher that observed by KK [19, 21]. In this commentary
we will refer to faint bands (trace readings) as positive.
Unfortunately, although both S. mansoni and S. haema-
tobium produce CCA, the POC-CCA assay is less reliable
in determining S. haematobium infection [22, 23]. This
may be due to different quantities of CCA produced by
each species or perhaps differences in the CCA from each
species in terms of clearance and urine concentrations.
Interestingly, one proof-of-concept report indicates that
the POC-CCA assay can be used to detect S. mekongi and
S. japonicum infections at reasonably high level of specifi-
city, albeit at similar levels of sensitivity as a Kato-Katz
assay [24]. A second publication focused on the detection
of Circulating Anodic Antigen (CAA) for detection of S.
japonicum in low prevalence areas of China indicated that
the POC-CCA assay did not show sufficient sensitivity to
be useful in this setting [25].
Using the POC-CCA to map S. mansoni infections leads to
new insights about prevalence, causes us to confront new
challenges and provides fresh opportunities
Based on multiple studies it has become clear that when
the prevalence by KK stool assay is below 50% the POC-
CCA assay detects many more S. mansoni infections [19].
When the egg-determined prevalence by KK is very low
(below 20%) the evidence from multiple studies indicates
that the worm-determined prevalence by POC-CCA is
often 3- to 6-fold higher [19]. This constitutes a major
challenge for national programs, because if they use preva-
lence cutoffs from the current WHO guidelines to dictate
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the appropriate programmatic response, they must con-
duct much more extensive and frequent MDA than if they
relied on KK prevalence; however, because guidance
incorporating experience with POC-CCA has not been
issued, programs are uncertain whether or not to do so.
In settings of low KK prevalence, many (some-
times >50%) of the POC-CCA positives are due to trace
readings, which are unlikely to indicate moderate or high-
intensity infections. Furthermore, it is unknown whether
some or many of the trace readings represent false
positives. To try to address this question in the situation
presented by schistosomiasis, i.e., without a gold standard,
is challenging. KK results cannot be used as a comparator,
because they are known to be insensitive in these circum-
stances. Several efforts have been made to determine the
false positive rate. Those assessments used the POC-CCA
in non-schistosomiasis endemic areas, where any positive
results likely represents false-positives (Ecuador and
non-endemic areas of Ethiopia). In those evaluations,
there was 1 trace reading out of 243 children, many of
these children had STHs but lived in schistosomiasis
non-endemic areas [26, 27].
Another approach is to use a laboratory-based assay for
Circulating Anodic Antigen (CAA) (which is also a prod-
uct of schistosome worms), which is thought to be even
more sensitive and more specific than the POC-CCA
assay [16, 18, 28] and that can then be used to examine
urines from people who are egg-negative but CCA-
positive. Such studies have been and are being done for S.
mansoni, but are not yet published (personal observation,
Daniel Colley). Using the Up-converting Phosphor (UCP)-
CAA assay as a “confirmatory” test the countrywide
prevalence obtained by testing a subsample of the urines
generally yields levels of prevalence that are 67 and 87% of
what was seen based on the POC-CCA cassette assay.
Thus, using the UCP-CAA assay as the best available
standard, the indication is that mapping with the POC-
CCA assay over-estimates the prevalence by ~ 15 to 30%
(personal observation, Daniel Colley and Carl Campbell).
Almost all readings of the POC-CCA assay of 1+ and
above correlate strongly with egg-positivity, and thus
provide solid antigenic evidence of viable worms. This,
however, still leaves a large proportion of the population be-
ing mapped as positive for having living worms in their
blood vessels, but without detectable schistosome eggs in
their stools on any given day. The daily variability of the
urine POC-CCA assay is substantially less than the variabil-
ity of the KK stool assay in detecting infection [26, 29, 30].
When there is no gold standard for diagnosis, another
way to compare the relative accuracy of two or more dif-
ferent assays is to estimate their most likely sensitivities
and specificities using a statistical approach called Latent
Class Analysis (LCA) [31–33]. The LCA uses information
from all tests results, then estimates a ‘true’ prevalence of
infection and calculates the most likely sensitivity and
specificity values for each competing test. This can be
done only if two or more different assays are recorded for
the same person each time. While the LCA may under-
estimate the specificity of an assay that is highly sensitive
relative to its comparators, it provides a more realistic
estimate of an assay’s diagnostic performance relative to
an unmeasured true infection status. By LCA, the POC-
CCA assay is consistently much more sensitive than KK.
Using LCA, the estimated specificity of the POC-CCA is
somewhat lower than for KK because the finding of an
egg is presumed to make the KK 100% specific [27, 34–36].
In terms of test sensitivity, however, a KK performed on
one or even three daily stools is known to provide only
mediocre detection of lightly infected subjects [37, 38]. This
means that it is in areas with very low prevalence (by KK)
that the higher sensitivity of the POC-CCA assay renders it
most valuable in terms of making programmatic decisions
about prevalence and in planning future interventions. As
further comparative studies are done with the KK,
POC-CCA, PCR [27], UCP-CAA, and antibody, assays, it
will be of great interest to evaluate these in parallel by LCA
to compare their performance and then find their optimal
use in schistosomiasis control programs.
What does it mean to find people (sometimes many
people) with low (or no) eggs by KK stool assays that
have schistosomes by detectable CCA?
It must always be remembered that these two assays
detect different life-cycle stages – the eggs and the worms –
and that it is possible to have worms without eggs, but not
possible to have excretion of eggs without worms (after a
suitable time period for egg excretion following effective
anti-worm treatment, usually thought to be ~ 2–3 weeks for
viable eggs and 4–6 weeks for dead eggs). Countries or
villages where most people have very low intensities of
infection by egg detection yet a substantial proportion of
those same individuals have detectable CCA in their urine
face a difficult programmatic decision. Part of the challenge
of this situation is the lack of current guidelines related to
newer assays. In part, this is related to a lack of sufficient
data to allow a full understanding of what this newly identi-
fied situation actually means. Also, it is due, in part, to a
lack of clarity regarding the programmatic goals, i.e., the
programmatic decision of whether to continue to provide
MDA to populations with very, very low worm burdens
may be different in programs still controlling morbidity as
compared to those seeking to achieve elimination. Such
decisions may also need to differ in different areas of
a given country.
Particularly as communities move towards elimination
of schistosomiasis based on KK or urine filtration, under-
standing the implications of “egg-negative schistosomiasis”
is going to be increasingly important. Without a true gold
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standard for detection of the number or status of worms
in such individuals, we will not know what the implica-
tions of this state are for the individual or for potential
transmission to others. Possible explanations for egg-
negative schistosomiasis are described in Table 1. The ap-
propriate response for the individual and for the public
health system depends on which of these is correct.
There is ample evidence for no.1 in Table 1, i.e., that the
KK stool exam is insensitive in low intensity infections
and that this can be due to intermittent egg excretion
[30, 39, 40] and/or a sampling error due to the uneven
distribution of eggs in a given stool sample [2]. The data
thus far regarding no. 2 in Table 1 are that the anti-CCA
monoclonal antibody used in the POC-CCA assay is quite
specific. However, most of the use of the monoclonal in
the commercial POC-CCA format has been done on
children and most of them would not be expected to have
widespread alternative causes of cross-reactivity (except
other NTDs which have been controlled for [26, 27]).
Thus, it is not yet possible to completely rule out some
potential cross-reactivity in adults. Number 3 in Table 1 is
potentially an explanation for some of the trace POC-
CCA readings because of individual visual acuity and/or
differential training as to what truly constitutes a trace
reading. The trace is, in fact, sometimes challenging to
read and could lead to reporting false-positives by some
readers, as well as false-positives even when multiple
readers agree. The information provided above regarding
the use of the “confirmatory” UCP-CAA assay would indi-
cate that this is perhaps a problem with some of trace
readings, but not the majority of them. Number 4 in the
Table reflects the finding that upon treatment with PZQ
some worms are damaged and experience temporary
suppression of oviposition but can subsequently rebound
and produce viable eggs, even months later [41]. Do
female worms go through menopause, or decline signifi-
cantly in their ability to produce eggs, while remaining
long-lived, as hypothesized in no. 5 of Table 1? We simply
do not know. Numbers 6 and 7 in Table 1 are both
possible, although single-sex female infections do not
develop to full maturity. Differential output of CCA by
males and females with females making more per worm
has been shown in vitro [42], but whether this is true of
intravascular dwelling worms is not known. Number 8 is
certainly a possibility because there is published epidemio-
logical- and modeling-based evidence for anti-fecundity
immunity that would reduce the production of eggs while
allowing continued adult worm infections [43, 44]. Also,
experimentally adult worm pairs that had ceased to
produce eggs in a very chronic baboon infection led to egg
excretion when the same worms were transplanted intra-
vascularly into a naïve baboon [45]. Other experimental
support for anti-fecundity immunity in chronic schisto-
some infections comes from the S. bovis literature [46, 47]
and candidate vaccine literature [48, 49]. Thus the inabil-
ity to make and excrete eggs in the chronic setting could
have been due to some level of anti-fecundity immunity.
What are the real questions about “egg-negative
schistosomiasis” for the development of public health
guidelines and the implementation of national programs?
If we take as a given that at low levels of prevalence and
intensity “egg-negative schistosomiasis” exists, the real
questions are: “What does this mean for such individuals
and what are its implications for NTD programs?”
Again, in part, the answers to those questions rest on a
need for more data to provide a better understanding of
why this situation exists and what it means. We posit
that “egg-negative schistosomiasis” is most likely to exist
because there are relatively few worms and they make
eggs either not at all or infrequently (no. 1a & no. 1b in
Table 1; possibly due to no. 5 and no. 8 in Table 1). The
literature tells us that even in places of higher prevalence
and intensity some infected individuals sporadically pro-
duce eggs in the stool and the number of eggs per gram
of stool varies extensively on a day-to-day basis [30, 39, 40].
Thus it follows that someone with very low worm
burdens (trace or 1+ by POC-CCA) may only excrete
eggs sporadically. However, it is challenging to prove
that this is the case. Perhaps they never produce eggs,
or perhaps they produce eggs sporadically, but never
excrete them. The latter situation will not be addressable
with current tools, but the former (i.e., sporadic produc-
tion/excretion of eggs by a few worms) can be asked by
doing very laborious but important consecutive stool
assays (by KK microscopically and by doing Hatch Tests
with larger volumes of stool to observe miracidial hatch-
ing) over weeks or even months. The information
obtained by such studies in very low prevalence and
Table 1 How can someone be Kato-Katz egg-negative and
POC-CCA-positive?
1. The KK is insensitive and missed an egg:
a) the egg was in another part of the stool
b) the egg was excreted on a different day
2. The POC-CCA is not sufficiently specific:
Because the anti-CCA mAb reacted with the CCA epitope produced in
another situation (Pregnancy, Infection, Tumors, Autoimmune diseases,
etc.)(most studies have been done in children)
3. The POC-CCA readers/technicians were insufficiently trained or trained
differently in different programs/teams; and trace readings are difficult
to determine
4. Temporary suppression of egg-production by worms damaged, but
not killed by praziquantel treatment
5. The female worms went through menopause
6. All immature or stunted female infections
7. All male infections
8. Anti-fecundity immunity reduced or stopped egg production
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intensity areas will be important for individuals and a
control program, and especially for an elimination
program. Such extensive, longitudinal stool collections
and assays have been done in the past, but in areas with
higher prevalence and intensity infections and only up to
about 10 days’ time [30, 39, 40].
Why would such data be so important for an infected
individual? An individual harboring a few worms that
are not producing eggs may not experience health
consequences, but if these worms do sporadically
produce eggs (whether they are excreted or not) the
person may continue to have chronic inflammatory
responses to schistosome eggs that are known to cause
anemia [50], and therefore they would be at continued
risk of morbidity due to schistosomiasis [51–53].
The different implications of no eggs excreted vs. spor-
adic excretion of eggs by a few worms have perhaps even
greater public health implications as national programs
move to eliminate schistosomiasis. The level of impact
of sporadic excretion of eggs rests on the biology of the
life cycle of schistosomes and the goals of the national
program involved. The major multiplicative phase of the
life cycle of schistosomes takes place within the inter-
mediate host, the snail vector. Thus, one person sporad-
ically passing eggs in their stool and contaminating a
fresh water environment in which susceptible host snails
exist is sufficient to maintain a continuing life cycle in a
community. This, obviously, would not allow the elimin-
ation of transmission – or at the very least it would
mean there would be a very long time to achieve R0 or
the nirvana of a “break-point”.
More sensitive assays always require re-calibration of
appropriate guidelines
Understanding “egg-negative schistosomiasis,” especially
in low prevalence, low intensity areas, is therefore a
primary need, both in regard to individual morbidity and
in terms of national programs regarding what and how
to move to elimination. Without additional data on the
occurrence and/or frequency of egg excretion by those
people harboring antigen-producing (CAA and CCA)
schistosome worms, the best that can be done is to use
the data available. In Burundi [21], Rwanda [54] and
Egypt [55], extensive school surveys using KK stool and
POC-CCA urine assays indicate that long-term (8 to
25 years) mass drug administration programs with PZQ
can achieve national or regional prevalence levels of 1-
2% by KK, but that concomitantly in these communities,
levels by POC-CCA are much higher (ranging from 10
to 80%). The current WHO guidelines for morbidity
control of S. mansoni infections, based on prevalence
and intensity by KK, are generally not useful in these
settings and are certainly not useful for moving towards
elimination, nor were they developed for this new goal.
We currently do not know the egg excretion potential of
those in areas such as Burundi, Rwanda and the Nile
delta of Egypt who are egg-negative by KK and positive
by trace POC-CCA (egg-/CCA-trace). If the goal of a
program is elimination, it is probably prudent to assume
that transmission can and will continue if these individ-
uals are not treated. This is because they may be excret-
ing eggs sufficiently, albeit sporadically, to perpetuate
transmission. It is simply not known if they are or are
not a threat to elimination. Thus, guidance for an elim-
ination program might be to continue annual or more
frequent MDAs (or move to test and treat alternatives
involving household or work group members) with PZQ
and institute other transmission control efforts such as
focal snail control and intensive behavior change along
with water and sanitation efforts. If the program decides
it is not yet ready to move towards elimination, but it
needs to continue to focus on morbidity control and to
lower prevalence and intensity to a point that elimin-
ation can be approached, then the guidance might be to
continue with annual MDA in areas of a given moderate
POC-CCA prevalence, for example above 20%, until the
move toward elimination is decided upon.
A “straw man” proposal when using mapping by POC-
CCA prevalence might be:
To gain or maintain control of schistosomiasis:
Annual or more frequent MDA is appropriate for any
area with >20% by POC-CCA
To move to elimination of schistosomiasis: Variations
of test and treat plus “adjunct” means of control in areas
with <20% by POC-CCA
To eliminate schistosomiasis transmission: Broad-
based test and treat plus “adjunct” means of control in
areas with <10% by POC-CCA
To assume elimination of transmission: Broad-based
determination of <10% by POC-CCA using an agreed
upon mapping strategy and confirmed by subsampling
and use of a more sensitive and specific assay at less
than 1–2%
To obtain verification and maintain elimination: Broad-
based/sentinel site surveillance for human exposure (with
POC-CCA or UCP-CAA or detection of antibodies in
young children) and/or xenomonitoring (by molecular
assays) for at least 3 years (verification) and indefinitely,
perhaps on an every other year basis (maintenance of
elimination status)
This “straw man” proposal is only that. It is not meant to
suggest that these are the correct thresholds or intervention
strategies. Perhaps they are, and more likely they are not. It
is only intended to provide fuel to initiate discussions in the
community of investigators, program managers, public
health and funding administrators concerned about where
control and elimination of schistosomiasis is headed over
the next 3-5 years. It is clear that not all countries, or even
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all districts/regions of a country, are at the same level in
regard to the gaining, maintaining, moving towards elimin-
ation, eliminating and maintaining the surveillance needed
for elimination. Thus the guidelines need to encompass
multiple different epidemiologic situations, levels of polit-
ical commitment and goals. It is also clear from progress in
many different infectious and chronic diseases that as new
mapping and diagnostic tools are developed that are more
sensitive and specific, the guidelines need to be regularly
re-assessed rather than written-in-stone, and re-formulated
as needed, to encompass our improved ability to discern
the actual situation in the field.
Conclusion
This is an exciting and an exasperating time for national
NTD programs, donors and other stakeholders that deal
with control and the potential elimination of schisto-
somiasis. The excitement is clear. Much of the drug
needed is donated, most endemic countries have devel-
oped appropriate NTD strategic plans and most have
also started MDA programs at some level. A consider-
able portion of the funding needed for implementation
of the plans is available through various agencies, as well
as the endemic countries themselves. This is an unprece-
dented time and the opportunity to truly alleviate some
of the world’s most impoverished populations of their
schistosomes is here. At the same time, with newer tools
and new studies we now know accomplishing the goal of
elimination of schistosomiasis will be even more challen-
ging than was anticipated. Current, available tools tell us
there is more “out there” than we thought, and the
studies reconfirm what those in the schistosomiasis field
have known all along, that distribution of the infection is
very focal and not all locations respond to control
measures equally. Nevertheless, the time is right to push
ahead. However, depending upon the current country
prevalence levels and the focal distributions of infection,
deciding between controlling morbidity or moving
towards elimination and surveillance will be difficult
decisions. As with any public health program, whether it
is to control, eliminate or eradicate, continued research
– both basic and operational – is needed throughout the
campaign. As a great spokesman for baseball and
philosophy once said, “It ain’t over ‘til its over” [56] and
that means you will always need new insights and tools
and the trick is to be flexible enough and open enough
to know how best to use them – until your goal is
accomplished.
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